Yahoo Financeยท2025-10-14 11:53AstraZeneca - AstraZeneca has entered into a U.S. drug pricing agreement with the Trump Administration, allowing the company to sell drugs to Medicaid at a discount and participate in a government website for lower cash prices [2] - The deal postpones tariffs on AstraZeneca drugs for three years due to the ongoing "Section 232" investigation [2] Novo Nordisk - An Indiana manufacturing plant owned by Novo Nordisk received an "official action indicated" letter from the FDA, indicating non-compliance and affecting multiple biotech companies [2] - The FDA has already delayed or rejected drug approvals from Scholar Rock and Regeneron Pharmaceuticals due to issues at the Novo Nordisk facility, raising concerns about Regeneron's timelines for label expansions [2] - Novo Nordisk is closing its cell therapy division, resulting in 250 layoffs and the discontinuation of a project aimed at curing Type 1 diabetes [2] Novavax - Shah Capital, a major shareholder owning 7.2% of Novavax, is urging the company to consider a sale due to ongoing underperformance and destruction of shareholder value [2] - The firm is calling for an immediate strategic review, suggesting that Novavax's assets could have greater potential under a larger pharmaceutical entity [2] - Novavax shares have significantly declined from nearly $300 during the pandemic to their current value [2]